Title
Date
- Korea Drug Classification Rule Update 2026: What MFDS’s Partial Amendment Means for Pharma Companies
- MFDS Fast‑Track 2026: Navigating GIFT Korea, Priority Review & Conditional Approval
- Korea Clinical Trial Strategy After MFDS 2025 Reforms: Why Korea is Becoming a Strategic Hub
- 2026 MFDS IND Approval Trends and Triple‑Agonist Clinical Trial Strategies in Korea
- Korea MFDS 2025 Drug Approval Reform: Faster Review Teams, Rolling Review and Updated Timelines
- 2025 Korea Drug Safety Regulation Updates: A Complete Guide for Practitioners